A046210 Stock Overview
HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
HLB PANAGENE Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,465.00 |
| 52 Week High | ₩6,720.00 |
| 52 Week Low | ₩3,005.00 |
| Beta | 0 |
| 1 Month Change | -14.30% |
| 3 Month Change | 11.90% |
| 1 Year Change | 25.25% |
| 3 Year Change | -20.27% |
| 5 Year Change | -2.83% |
| Change since IPO | -55.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| A046210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.8% | 4.1% | 0.5% |
| 1Y | 25.2% | 6.6% | 4.7% |
Return vs Industry: A046210 exceeded the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A046210 exceeded the KR Market which returned 4.7% over the past year.
Price Volatility
| A046210 volatility | |
|---|---|
| A046210 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A046210 has not had significant price volatility in the past 3 months.
Volatility Over Time: A046210's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | n/a | Sung-Ki Kim | www.panagene.com |
HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases.
HLB PANAGENE Co., LTD. Fundamentals Summary
| A046210 fundamental statistics | |
|---|---|
| Market cap | ₩183.13b |
| Earnings (TTM) | -₩6.82b |
| Revenue (TTM) | ₩29.88b |
0.0x
P/S Ratio0.0x
P/E RatioIs A046210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A046210 income statement (TTM) | |
|---|---|
| Revenue | ₩29.88b |
| Cost of Revenue | ₩27.82b |
| Gross Profit | ₩2.06b |
| Other Expenses | ₩8.88b |
| Earnings | -₩6.82b |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A046210 perform over the long term?
See historical performance and comparison